Clinical effect of short-term regimen containing levofloxacin in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis

doi:10.19983/j.issn.2096-8493.20210145

Abstract

Abstract:

Objective: To analyze the clinical effect of short-term regimen containing levofloxacin (Lfx) in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis. Methods: A prospective study was conducted in 132 newly diagnosed bacteria-positive pulmonary tuberculosis patients in Shantou Tuberculosis Prevention and Treatment Institution from January 2017 to December 2019. The patients were consecutively numbered and randomly divided into observation group (n=68) and control group (n=64). The control group was treated with routine 2H-R-Z-E/4H-R scheme (H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol), and the observation group was treated with 4.5Lfx-H-R-E-Z scheme. The cure rate, sputum negative conversion rate, focus absorption, incidence of adverse drug reactions and recurrence rate were compared between the two groups. Results: The cure rate of the observation group was 100.0% (68/68), which was significantly higher than that of the control group (90.6% (58/64))(Fisher’s exact probability method, P=0.011). The negative conversion rates of sputum bacteria in the observation group and the control group at the end of 2 months (8 weeks) of treatment were 97.1% (66/68) and 96.9% (62/64), respectively, with no significant difference (Fisher’s exact probability method, P>0.05). The total effective rate of lesion absorption was 100.0% (68/68) in the observation group and 90.6% (58/64) in the control group, with no significant difference (χ²=3.552, P=0.470). The incidence of adverse drug reactions in the observation group and the control group were 20.6% (14/68) and 18.8% (12/64), respectively, with no significant difference (χ²=0.070, P=0.791). After 2 years of follow-up, the recurrence rate was 2.9% (2/68) in the observation group and 3.1% (2/64) in the control group, with no significant difference (Fisher’s exact probability method, P=1.000). Conclusion: The short-term regimen containing Lfx is effective and safe in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis.

Key words: Tuberculosis,pulmonary, Quinolones, Drug therapy, Therapeutic uses

CLC Number:

R521
R978.3

CHEN Zhuang-hao, LIN Jian-xiong, ZENG Li-xiang. Clinical effect of short-term regimen containing levofloxacin in the treatment of newly diagnosed bacteria-positive pulmonary tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(1): 19-21. doi: 10.19983/j.issn.2096-8493.20210145

Figures/Tables 1

References 5

[1]	段鸿飞, 初乃惠. 抗结核药品临床试验疗效评价指标的研究进展. 中国防痨杂志, 2021, 43(1):96-99. doi: 10.3969/j.issn.1000-6621.2021.01.018. doi: 10.3969/j.issn.1000-6621.2021.01.018
[2]	许惠敏, 罗浓伟. 含左氧氟沙星方案治疗老年复治涂阳肺结核的临床价值. 北方药学, 2020, 17(3):132-133. doi: 10.3969/j.issn.1672-8351.2020.03.098. doi: 10.3969/j.issn.1672-8351.2020.03.098
[3]	Wallis RS, Peppard T, Hermann D. Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One, 2015, 10(4):e0125403. doi: 10.1371/journal.pone.0125403. doi: 10.1371/journal.pone.0125403 URL
[4]	Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One, 2013, 8(7):e67030. doi: 10.1371/journal.pone.0067030. doi: 10.1371/journal.pone.0067030 URL
[5]	Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, et al. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India. Clin Infect Dis, 2014, 59(10):e142-e149. doi: 10.1093/cid/ciu550. doi: 10.1093/cid/ciu550 URL

组别	例数	全吸[例 (构成比,%)]	显吸[例 (构成比,%)]	吸收[例 (构成比,%)]	不变[例 (构成比,%)]	恶化[例 (构成比,%)]	总有效[例 (有效率,%)]
观察组	68	46(67.6)	12(17.6)	10(14.8)	0(0.0)	0(0.0)	68(100.0)
对照组	64	36(56.3)	12(18.8)	10(15.6)	6(9.3)	0(0.0)	58(90.6)

[1]	DENG Guo-fang, LEI Jian-ping. Analysis on diagnosis and treatment of coronavirus disease 2019(COVID-19) [J]. Journal of Tuberculosis and Lung Health, 2020, 9(1): 7-10.
[2]	WANG Chun-ting, LI Ya-qi, MI Yan, MO Nian-chun, LIU Hong-yan, LE Xing, ZHOU Li, WU Bi-feng, HAN Shi-yun, BAI Li-qiong, ZHANG Chuan-fang. Monitoring of pulmonary function in patients with active tuberculosis during anti-tuberculosis treatment [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(1): 39-44.
[3]	Ni WANG,Fei HUANG,Hui ZHANG. Implementation electronic medication monitor in tuberculosis medication management [J]. Journal of Tuberculosis and Lung Health, 2019, 8(4): 244-248.
[4]	Song YANG,Xiao-feng YAN. Current status and future prospects on the treatment of multi/extensively drug-resistant tuberculosis with bedaquiline [J]. Journal of Tuberculosis and Lung Health, 2019, 8(4): 249-252.
[5]	MA Jin-bao,MA Ting-ting,REN Fei,YANG Hong.. Analysis of hypokalemia caused by capreomycin in patients with multidrug-resistant tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2019, 8(3): 183-187.
[6]	Shuang LIANG,Dong-wei HAN,Wei ZHONG,Ning MAO,Yi LIU,Yi-wen JIANG. Analysis of effect of FDC chemethorapy combined with levofloxacin in patients with smear positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2019, 8(2): 149-152.
[7]	Yu CHEN,Li-chao FAN,Yu CHEN,Ya-juan ZHU. Continuous lumbar drainage in the treatment of tuberculous meningitis [J]. Journal of Tuberculosis and Lung Health, 2018, 7(3): 221-224.
[8]	Li-hua ZHENG,Jing-lai YU,Peng SUN,Hong-qing LI,Dong CHEN,Ying-jie YU,Sha NI,Ming XU,Yan CHENG,Chun-guang MA,Chun-yu ZHAO,Na YANG,Gui-jiao LI,Juan. LI. Clinical efficacy analysis of Qingfei Qulao Pill in the treatment of patients with relapsed pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2018, 7(2): 114-119.
[9]	Su-hua. MENG. Clinical efficacy of local drug administration by bronchfiberscope combined with chemotherapy in the treatment of multi-drug resistant pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2018, 7(2): 146-148.
[10]	CHENG Yan-zhi,LIU Qun-qun, MIAO Yan-fang, TANG Shen-jie. Advances in the study of fluoroquinolones in the treatment of tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2017, 6(3): 275-278.
[11]	TANG Shen-jie. Shortening the treatment course of tuberculosis: past, present and future [J]. Journal of Tuberculosis and Lung Health, 2016, 5(1): 19-.
[12]	KUANG Hao-bin, TAN Shou-yong, XIE Yu-hong, WANG Min, ZHANG Hong, YUAN Yuan, LI Yan, QIN Hong-juan, FENG Zhi-yu, YE Jin-quan. Adverse drug reactions of chemotherapy and treatment in patients with multidrug resistant tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2015, 4(4): 219-222.
[13]	DENG Zhang-li, WU Dao-shen, LI Yan-liang, TAN Wei-guo. Discussion of the clinical features of 110 cases with drug-resistant tuberculosis [J]. Journal of Tuberculosis and Lung Health, 2015, 4(2): 113-115.
[14]	LI Bing, BAO Feng-yu. The influence of PRECEDE-PROCEED model on the therapeutic compliance of MDR-TB patients [J]. Journal of Tuberculosis and Lung Health, 2015, 4(2): 116-120.
[15]	FAN Xiang-yang. Clinical analysis of pulmonary tuberculosis complicated with fungal infection [J]. Journal of Tuberculosis and Lung Health, 2015, 4(2): 130-132.